Graham Capital Management, L.P. Fate Therapeutics Inc Transaction History
Graham Capital Management, L.P.
- $5.17 Billion
- Q2 2025
A detailed history of Graham Capital Management, L.P. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Graham Capital Management, L.P. holds 85,633 shares of FATE stock, worth $110,466. This represents 0.0% of its overall portfolio holdings.
Number of Shares
85,633
Previous 140,064
38.86%
Holding current value
$110,466
Previous $110,000
13.64%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding FATE
# of Institutions
152Shares Held
83.4MCall Options Held
179KPut Options Held
13.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$16.6 Million1.75% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$13 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$11.3 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.54MShares$5.86 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.4MShares$4.38 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $125M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...